Annexon inc

US StockHealth Care

ANNX AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.

ANNX Current Performance

5.00%

Annexon inc

0.68%

Avg of Sector

0.03%

S&P500

Top 10 High Relevance to ANNX

  • FTRE Fortrea holdings inc
    Value -Trend 5Swing Trading 5Whale Interest 3Dividend 1
    See more

ANNX Profile

Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is also evaluating ANX005 for the potential treatment of patients with Huntington's disease (HD). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications.

Price of ANNX